Obestatin/ghrelin ratio: A new activity index in inflammatory bowel diseases

Inflammatory Bowel Diseases

Volumn 15, Issue 10, 2009, Pages 1557-1561

  Alexandridis, Efstratios ^a   Zisimopoulos, Athanasios ^b   Liratzopoulos, Nikolaos ^b   Katsos, Ioannis ^a   Manolas, Konstantinos ^b   Kouklakis, Georgios ^b  

^a Theageneion Anticancer Hospital of Thessaloniki   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Ghrelin; Inflammatory bowel disease; Obestatin; Ratio; Serum level

Indexed keywords

GHRELIN; OBESTATIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ACTIVITY; ENTERITIS; HUMAN; MAJOR CLINICAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; REMISSION; SCORING SYSTEM; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GHRELIN; HUMANS; MALE; MIDDLE AGED; PEPTIDE HORMONES; PROGNOSIS; REMISSION INDUCTION; YOUNG ADULT;

EID: 70450175683     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20940     Document Type: Article

References (24)

1. Desreumaux P, Ernst O, Geboes K, et al. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology. 1999;117:73-81. (Pubitemid 29297622)
2. Forbes A. Crohn's disease: the role of nutritional therapy. Aliment Pharmacol Ther. 2002;16(suppl 4):48-52.
3. Karmiris K, Koutroubakis IE, Xidakis C, et al. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:100-105.
4. Karmiris K, Koutroubakis IE, Kouroumalis EA. The emerging role of adipocytokines as inflammatory mediators in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:847-855. (Pubitemid 41368274)
5. Nagaya N, Uematsu M, Kojima M, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation. 2001;104:2034-2038. (Pubitemid 33027043)
6. Ates Y, Degertekin B, Erdil A, et al. Serum ghrelin levels in inflammatory bowel disease with relation to disease activity and nutritional status. Dig Dis Sci. 2008;53:2215-2221.
7. Tritos NA, Kokkotou EG. The physiology and potential clinical applications of ghrelin, a novel peptide hormone. Mayo Clin Proc. 2006;81:653-660.
8. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev. 2005;85:495-522.
9. Smith RG. Growth hormone releasing substances: types and their receptors. Horm Res. 1999;51(suppl 3):1-8.
10. Zhang JV, Ren PG, Avsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science. 2005;310:996-999. (Pubitemid 41611907)
11. Zhang JV, Jahr H, Luo CW, et al. Obestatin induction of early response gene expression in gastrointestinal and adipose tissues and the mediatory role of GPR39. Mol Endocrinol. 2008;22:1464-1475. (Pubitemid 351787005)
12. Theiss AL, Fruchtman S, Lund PK. Growth factors in inflammatory bowel disease: the actions and interactions of growth hormone and insulin-like growth factor-I. Inflamm Bowel Dis. 2004;10:871-880. (Pubitemid 39545231)
13. Han X, Benight N, Osontokun B, et al. Tumor necrosis factor alpha blockade induces an anti inflammatory growth hormone signaling pathway in experimental colitis. Gut. 2007;56:73-81. (Pubitemid 46044891)
14. Katsanos KH, Tsatsoulis A, Christodoulou D, et al. Reduced serum insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 levels in adults with inflammatory bowel disease. Growth Horm IGF Res. 2001;11:364-367. (Pubitemid 34428879)
15. Tenore A, Berman WF, Parks JS, et al. Basal and stimulated serum growth hormone concentrations in inflammatory bowel disease. J Clin Endocrinol Metab. 1977;44:622-628. (Pubitemid 8088093)
16. Capristo E, Farnetti S, Mingrone G, et al. Reduced plasma ghrelin concentration in celiac disease after gluten-free diet treatment. Scand J Gastroenterol. 2005;40:430-436. (Pubitemid 40546910)
17. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989;24(suppl):2-6.
18. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
19. Walmsey RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29.
20. Hosomi S, Oshitani N, Kamata N, et al. Phenotypical and functional study of ghrelin and its receptor in the pathogenesis of Crohn's disease. Inflamm Bowel Dis. 2008;14:1205-1213.
21. Ballinger AB, Camacho-Hubner C, Croft NM. Growth failure and intestinal inflammation. Q J Med. 2001;94:121-125.
22. Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A, et al. Antitumour necrosis factor {alpha} therapy modulates ghrelin in patients with severe rheumatoid arthritis. Ann Rheum Dis. 2008;67:1644-1646.
23. Sung E, DA Silva NF, Goodyear S, et al. Increased plasma ghrelin following infliximab in Crohn's disease. Aliment Pharmacol Ther. 2008 (in press).
24. Moechars D, Depoortere I, Moreaux B. Altered gastrointestinal and metabolic function in the GPR39-obestatin receptor-knockout mouse. Gastroenterology. 2006;131:1131-1141. (Pubitemid 44498686)